The SA Journal Diabetes & Vascular Disease Vol 11 No 4 (November 2014)

16 / 44

150 VOLUME 11 NUMBER 4 • NOVEMBER 2014
REVIEW SA JOURNAL OF DIABETES & VASCULAR DISEASE
References
1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new
paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4):
773–795.
2. Meier JJ, Ueberberg S, Korbas S, Schneider S. Diminished glucagon suppression
after [beta]-cell reduction is due to impaired [alpha]-cell function rather than an
expansion of [alpha]-cell mass. Am J Physiol Endocrinol Metab 2011; 300(4):
E717–E723.
3. Ferrannini E. The stunned beta cell: a brief history. Cell Metab 2010; 11: 349–
352.
4. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical
prospects. Nat Rev Endocrinol 2012; 8(8): 495–502.
5. Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp
Med Biol 2012; 771: 42–50.
6. IDF.
26. INVOKANA Prescribing Information 2013; data on file. Data on file, Janssen
Pharmaceuticals, Inc, Titusville, NJ.
7. Mbanya JC, Motala AA, Sobngwi E, Assah FK, Enoru ST. Diabetes in sub-Saharan
Africa. Lancet 2010; 375(9733): 2254–2266.
8. Hall V, Thomsen RW, Henriksen O, Lohse N. Diabetes in Sub Saharan Africa 1999–
2011: epidemiology and public health implications. A systematic review. BMC
Public Health 2011; 11: 564.
9. Liday C. Overview of the guidelines and evidence for the pharmacologic
management of type 2 diabetes mellitus. Pharmacotherapy 2011; 31(Suppl 12):
37S–43S.
10. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical
and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48(5):
643–648.
11. American Diabetes Association. Standards of medical care in diabetes – 2013.
Diabetes Care 2013; 36 (Suppl 1): S11–66.
12. Amod A, Ascott-Evans BH, Berg GI, Blom DJ, Brown SL, Carrihill MM, et al;
Guideline Committee. J Endocrinol Metab Dis Sth Afr 2012; 17(2)(Suppl 1):
S1–S95.
13. McGill JB. Pharmacotherapy in type 2 diabetes: a functional schema for drug
classification. Curr Diabetes Rev 2012; 8(4): 257–267.
14. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN. Quantitative
PCR tissue expression profiling of the human SGLT2 gene and related family
members. Diabetes Ther 2010; 1(2):57–92.
15. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters.
Physiol Rev 2011; 91(2): 733–794.
16. Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors
in the treatment of type 2 diabetes mellitus. Curr Diab Rep 2012; 12(3): 230–
238.
17. Gerich JE. Role of the kidney in normal glucose homeostasis and in the
hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010;
27(2): 136–142.
18. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose
transporters in human renal proximal tubular cells isolated from the urine of
patients with non-insulin-dependent diabetes. Diabetes 2005; 54(12): 3427–
3434.
19. Forxiga SMPC; Date
accesed 01/10/2013
20. Dapagliflozin FDA briefing document July 2011.
DOWNLOADS/ADVISORYCOMMITTEES/COMMITTEESMEETINGMATERIALS/
DRUG S/ENDOCRINOLOGICANDMETABOLICDRUGSADVISORYCOMMITTEE/
UCM262994.PDF. Date accessed 01/10/2013.
21. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in
type 2 diabetic patients with inadequate glycemic control by diet and exercise: a
randomized, double-blind, placebo-controlled, Phase 3 trial. Diabetes Care 2010;
33(10): 2217–2224.
22. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2
inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type
2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care
2012; 35(7): 1473– 1478.
23. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin
006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2
diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern
Med 2012; 156(6): 405–415.
24. Canaglilfozin FDA briefing document.
AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrin
ologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf Date accessed
01/10/2013.
25. INVOKANA Prescribing Information 2013; data on file. Data on file, Janssen
Pharmaceuticals, Inc., Titusville, NJ.
26. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in
type 2 diabetic patients with inadequate glycemic control by diet and exercise:
a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33,
2217–2224 (2010).
27. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients
with type 2 diabetes who have inadequate glycaemic control with metformin:
a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375(9733):
2223–2233.
28. Strojek K, Yoon KH, Hruba V, ElzeM, Langkilde AM, Parikh S. Effect of dapagliflozin
in patients with type 2 diabetes who have inadequate glycaemic control with
glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
Diabetes Obes Metab 2011; 13: 928–938.
29. Kim Y, Babu AR Clinical potential of sodium-glucose cotransporter 2 inhibitors
in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012; 5:
313–327.
30. Jones D. Diabetes field cautiously upbeat despite possible setback for leading
SGLT2 inhibitor. Nat Rev Drug Discov 2011; 10(9): 645–664.
31. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ.
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’
treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes
Obes Metab 2013; 15(7): 613–621.
32. Bolinder J, et al. Effects of dapagliflozin on body weight, total fat mass, and
regional adipose tissue distribution in patients with type 2 diabetes mellitus with
inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97:
1020–1031.
33. List JF, Woo V, Morales E, TangW, Fiedorek FT. Sodium-glucose cotransport inhibition
with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32(4): 650–657.
The management and staff of Clinics Cardive Publishing wish you and
your family a wonderful holiday season and a healthy and peaceful
2015. May your holidays be filled with joy, peace and
good cheer!
We take this opportunity to thank
you for your loyal support during
2014 and we look forward to being
of service in 2015.